Table 1.
Patient characteristics of all 108 NSCLC patients treated with SRT concurrent to TT/IT
| N (%), median (range) | |
|---|---|
| All patients (n = 108) | |
| Age (years) | 63 (33–80) |
| Histology subtype | |
| ADC | 80 (74) |
| LCNEC | 3 (3) |
| SqCC | 6 (6) |
| Adenosquamous | 3 (3) |
| Unknown | 16 (15) |
| Synchronous metastatic disease | |
| Yes | 81 (75) |
| No | 27 (25) |
| Ligand expression/driver mutation | |
| EGFR | 49 (45) |
| ALK | 16 (15) |
| ROS1 | 2 (2) |
| PD-L1 | 5 (5) |
| No | 30 (28) |
| Unknown | 5 (5) |
| Previous systemic treatment lines | 1 (1–5) |
| Present metastases | |
| ≤ 5 | 53 (49) |
| > 5 | 55 (51) |
| Involved organs | 2 (1–7) |
| Status of primary tumor | |
| Controlled | 75 (69) |
| Progressive | 26 (24) |
| Unknown | 7 (7) |
| SRT treated lesions | |
| Brain | 144 (75) |
| Lymph nodes | 3 (2) |
| Lung | 18 (9) |
| Liver | 6 (3) |
| Adrenal gland | 3 (2) |
| Bone | 17 (9) |
| Soft tissue | 1 (0.5) |
| SRT treated lesions per patient | |
| Cranial | 1 (1–5) |
| Extracranial | 1 (1–3) |
| Type of systemic therapy | |
| EGFR/ALK-inhibitor | 65 (60) |
| PD-1/PD-L1-inhibitor | 33 (31) |
| Anti-VEGF-antibody | 9 (8) |
| PARP-inhibitor | 1 (1) |
| Prescribed BED10 (Gy) | |
| Cranial | 75 (26.6–113.9) |
| Extracranial | 95.3 (53.1–180) |
| Total GTV volume (cc) | |
| Cranial | 1.2 (0.04–15.3) |
| Extracranial | 8.4 (0.5–86.1) |
ADC adenocarcinoma, LCNEC large cell neuroendocrine carcinoma, SqCC squamous cell carcinoma